EE05452B1 - Triamiidasendatud indoolid, bensofuraanid ja bensotiofeenid kui mikrosomaalse trigltseriidide transportvalgu (MTP) ja/v?i apolipoproteiin B (apoB) sekretsiooni inhibiitorid - Google Patents

Triamiidasendatud indoolid, bensofuraanid ja bensotiofeenid kui mikrosomaalse trigltseriidide transportvalgu (MTP) ja/v?i apolipoproteiin B (apoB) sekretsiooni inhibiitorid

Info

Publication number
EE05452B1
EE05452B1 EEP200400040A EEP200400040A EE05452B1 EE 05452 B1 EE05452 B1 EE 05452B1 EE P200400040 A EEP200400040 A EE P200400040A EE P200400040 A EEP200400040 A EE P200400040A EE 05452 B1 EE05452 B1 EE 05452B1
Authority
EE
Estonia
Prior art keywords
benzothiophenes
benzofurans
apob
triamide
mtp
Prior art date
Application number
EEP200400040A
Other languages
English (en)
Inventor
Bertinato Peter
Elwood Blize Alan
Scott Bronk Brian
Cheng Hengmiao
Huatan Hiep
Li Jin
Philip Mason Clive
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200400040A publication Critical patent/EE200400040A/et
Publication of EE05452B1 publication Critical patent/EE05452B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
EEP200400040A 2001-06-28 2002-05-24 Triamiidasendatud indoolid, bensofuraanid ja bensotiofeenid kui mikrosomaalse trigltseriidide transportvalgu (MTP) ja/v?i apolipoproteiin B (apoB) sekretsiooni inhibiitorid EE05452B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30164401P 2001-06-28 2001-06-28
PCT/IB2002/001876 WO2003002533A1 (en) 2001-06-28 2002-05-24 Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion

Publications (2)

Publication Number Publication Date
EE200400040A EE200400040A (et) 2004-06-15
EE05452B1 true EE05452B1 (et) 2011-08-15

Family

ID=23164253

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200400040A EE05452B1 (et) 2001-06-28 2002-05-24 Triamiidasendatud indoolid, bensofuraanid ja bensotiofeenid kui mikrosomaalse trigltseriidide transportvalgu (MTP) ja/v?i apolipoproteiin B (apoB) sekretsiooni inhibiitorid

Country Status (47)

Country Link
US (5) US6720351B2 (et)
EP (1) EP1404653B1 (et)
JP (1) JP4139325B2 (et)
KR (2) KR100575919B1 (et)
CN (2) CN1522246B (et)
AP (1) AP1649A (et)
AR (1) AR036158A1 (et)
AT (1) ATE405548T1 (et)
AU (1) AU2002307839B2 (et)
BG (1) BG108487A (et)
BR (1) BR0210616A (et)
CA (1) CA2451474C (et)
CR (1) CR7151A (et)
CY (1) CY1108407T1 (et)
CZ (1) CZ20033558A3 (et)
DE (1) DE60228447D1 (et)
DK (1) DK1404653T3 (et)
EA (1) EA007008B1 (et)
EC (1) ECSP034925A (et)
EE (1) EE05452B1 (et)
ES (1) ES2307799T3 (et)
GE (2) GEP20053720B (et)
GT (1) GT200200136A (et)
HK (2) HK1096665A1 (et)
HR (1) HRP20031051B1 (et)
HU (1) HU229551B1 (et)
IL (1) IL158516A0 (et)
IS (1) IS2603B (et)
MA (1) MA27045A1 (et)
MX (1) MXPA03011707A (et)
MY (1) MY129328A (et)
NO (1) NO326700B1 (et)
NZ (1) NZ528752A (et)
OA (1) OA12626A (et)
PA (1) PA8549301A1 (et)
PE (1) PE20030135A1 (et)
PL (1) PL367680A1 (et)
PT (1) PT1404653E (et)
RS (1) RS50712B (et)
SI (1) SI1404653T1 (et)
SK (1) SK287806B6 (et)
TN (1) TNSN03146A1 (et)
TW (2) TWI313264B (et)
UA (1) UA75660C2 (et)
UY (1) UY27360A1 (et)
WO (1) WO2003002533A1 (et)
ZA (1) ZA200307818B (et)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
TNSN03146A1 (fr) * 2001-06-28 2005-12-23 Pfizer Prod Inc Indoles, benzofurannes et benzothiophenes a substituant triamide, utiles comme inhibiteurs de secretion de la proteine de transfert des triglycerides microsomaux et/ou de l'apolipo-proteine b (apo b).
WO2003057175A2 (en) * 2002-01-02 2003-07-17 Visen Medical, Inc. Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor
CA2515368A1 (en) * 2003-02-13 2004-08-26 Luciano Rossetti Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
EP1631269A4 (en) * 2003-05-20 2007-09-12 Erimos Pharmaceutical Llp METHODS AND COMPOSITIONS FOR THE ADMINISTRATION OF CATECHOLIC BUTANAS FOR THE TREATMENT OF OBESITY
EP1636592B1 (en) 2003-06-19 2012-12-19 Merck Serono SA Use of prion conversion modulating agents
EP1696887A1 (en) * 2003-11-14 2006-09-06 Pfizer Products Inc. Solid amorphous dispersions of an mtp inhibitor for treatment of obesity
CA2555133A1 (en) 2004-02-04 2005-09-01 Pfizer Products Inc. Substituted quinoline compounds
US7932268B2 (en) 2004-03-05 2011-04-26 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
FR2873694B1 (fr) * 2004-07-27 2006-12-08 Merck Sante Soc Par Actions Si Nouveaux aza-indoles inhibiteurs de la mtp et apob
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
US20070026079A1 (en) * 2005-02-14 2007-02-01 Louis Herlands Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
EP1890767A2 (en) * 2005-05-27 2008-02-27 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
US7417066B2 (en) 2005-06-08 2008-08-26 Schering Ag Inhibitors of soluble adenylate cyclase
DE102005027274A1 (de) * 2005-06-08 2006-12-14 Schering Ag Inhibitoren der löslichen Adenylatzyklase
JP2009503050A (ja) * 2005-08-04 2009-01-29 ファイザー・リミテッド ピペリジノイル−ピロリジンおよびピペリジノイル−ピペリジン化合物
JP2009511635A (ja) * 2005-10-18 2009-03-19 エージェリオン ファーマシューティカルズ 哺乳動物における高脂血症に関連する障害を治療するための方法
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US20090111778A1 (en) * 2005-11-18 2009-04-30 Richard Apodaca 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US9913917B2 (en) 2005-12-22 2018-03-13 Visen Medical, Inc. Biocompatible fluorescent metal oxide nanoparticles
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
DK2674428T3 (en) * 2006-04-07 2016-04-18 Vertex Pharma Modulators of ATP binding cassette transporters
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
AU2007320906A1 (en) 2006-11-13 2008-05-22 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
WO2008079398A1 (en) * 2006-12-21 2008-07-03 Aegerion Pharmaceuticals, Inc. Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor
ES2670852T3 (es) 2007-02-09 2018-06-01 Visen Medical, Inc. Colorantes con policiclo y uso de los mismos
WO2008100423A1 (en) * 2007-02-09 2008-08-21 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
EP2155643B1 (en) 2007-06-08 2016-08-10 MannKind Corporation Ire-1a inhibitors
WO2009014674A1 (en) * 2007-07-23 2009-01-29 Sirtris Pharmaceuticals, Inc. Heterocyclylamides as gut microsomal triglyceride transport protein inhibitors
US20100286200A1 (en) * 2008-01-16 2010-11-11 Janssen Pharmaceutica Nv Combination of metformin and an mtp inhibitor
US20090197947A1 (en) * 2008-02-01 2009-08-06 The Research Foundation Of State University Of New York Medicaments and methods for lowering plasma lipid levels and screening drugs
JP5711151B2 (ja) * 2010-01-06 2015-04-30 武田薬品工業株式会社 インドール誘導体
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2569678C2 (ru) 2010-04-22 2015-11-27 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
EP2665708A4 (en) * 2011-01-20 2014-07-09 Univ Colorado Regents MODULATORS OF THE TLR3 / DSRNA COMPLEX AND APPLICATIONS THEREOF
CN102108070B (zh) * 2011-01-26 2013-05-22 上海优贝德生物医药有限公司 5-氨基苯并呋喃-2-甲酸酯及其中间体的制备方法
EP2872122A1 (en) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
EP2963013A4 (en) 2013-02-27 2016-09-14 Shionogi & Co INDOLE AND AZAINDOLE DERIVATIVES HAVING AMPK ACTIVATION ACTIVITY EACH
WO2015121877A2 (en) * 2014-02-17 2015-08-20 Hetero Research Foundation Polymorphs of lomitapide and its salts
CN103880797B (zh) * 2014-03-26 2015-12-02 沈阳大学 苯并呋喃类化合物及其医药用途
PL3424534T3 (pl) 2014-04-15 2021-11-22 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
CN112279808B (zh) 2014-10-06 2024-03-08 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
WO2017173274A1 (en) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
PE20191147A1 (es) 2016-09-30 2019-09-02 Vertex Pharma Modulador de regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmaceuticas, metodos de tratamiento y proceso para producir el modulador
SG10201913606VA (en) 2016-12-09 2020-02-27 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CA3066084A1 (en) 2017-06-08 2018-12-13 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2019018395A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated METHODS OF TREATING CYSTIC FIBROSIS
ES2912657T3 (es) 2017-08-02 2022-05-26 Vertex Pharma Procesos para preparar compuestos de pirrolidina
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
MX2020005753A (es) 2017-12-08 2020-08-20 Vertex Pharma Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CN112608271A (zh) * 2020-11-26 2021-04-06 安润医药科技（苏州）有限公司 酰胺衍生物及其在制备ep4受体拮抗剂中的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022900A (en) 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
US4397855A (en) 1981-06-26 1983-08-09 Warner-Lambert Company 4-(Substituted)-α, α-dimethyl-1-piperazine pentanoic acids and derivatives as anti-arteriosclerotic agents and method
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US5416009A (en) 1991-01-23 1995-05-16 The United States Of America Nucleotide molecule encoding a specific Onchocerca volvulus antigen for the immunodiagnosis of onchocerciasis
CA2091102C (en) 1992-03-06 2009-05-26 John R. Ii Wetterau Microsomal triglyceride transfer protein
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
GB9225141D0 (en) 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
FR2723739B1 (fr) * 1994-08-19 1997-02-14 Sanofi Sa Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
WO1996040640A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
MX9709914A (es) 1995-06-07 1998-03-31 Pfizer Derivados de acido bifenil-2-carboxilico-tetrahidro-isoquinolin-6-ilo, su preparacion y el uso de los mismos.
ES2191706T3 (es) 1995-06-07 2003-09-16 Pfizer Derivados de tetrahidro-isoquinolinil-6-il amida del acido bifenil-2-carboxilico, su preparacion y su uso como inhibidores de la proteina de transferencia de trigliceridos microsomal y/o secrecion de apolipoproteina b (apo b).
JP2000505360A (ja) 1996-02-02 2000-05-09 ブリギッテ メリット 塑性的な材料から成るストランドを加工するための装置
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
EP0944602A1 (en) 1996-11-27 1999-09-29 Pfizer Inc. Apo b-secretion/mtp inhibitory amides
WO1998027979A1 (en) 1996-12-20 1998-07-02 Bristol-Myers Squibb Company Heterocyclic inhibitors of microsomal triglyceride transfer protein and method
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US5968950A (en) 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
TW460478B (en) * 1997-08-15 2001-10-21 Chugai Pharmaceutical Co Ltd Phenethylamine derivatives
JP2959765B2 (ja) 1997-12-12 1999-10-06 日本たばこ産業株式会社 ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
DE69829879T2 (de) 1997-12-24 2006-03-02 Sanofi-Aventis Deutschland Gmbh Indolderivate als faktor xa inhibitoren
EP1080724A4 (en) 1998-05-22 2004-06-23 Nippon Shinyaku Co Ltd COMPOSITIONS FOR REDUCING MTP ACTIVITY
CA2319495A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
CO5090829A1 (es) * 1998-07-21 2001-10-30 Novartis Ag Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
US6197798B1 (en) 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
CA2375920A1 (en) * 1999-06-14 2000-12-21 Eli Lilly And Company Compounds
DE19933926A1 (de) 1999-07-20 2001-01-25 Boehringer Ingelheim Pharma Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19945594A1 (de) * 1999-09-23 2001-03-29 Boehringer Ingelheim Pharma Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2325358C (en) * 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
DE19963234A1 (de) 1999-12-27 2002-01-24 Boehringer Ingelheim Pharma Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19963235A1 (de) * 1999-12-27 2001-07-05 Boehringer Ingelheim Pharma Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
ES2240420T3 (es) 2000-01-18 2005-10-16 Novartis Ag Carboxamidas utiles como inhibidores de la proteina de transferencia de trigliceridos microsomicos y de la secrecion de apolipoproteina b.
WO2001077077A1 (en) 2000-04-10 2001-10-18 Novartis Ag Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
GB0013378D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
GB0013383D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0013346D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
US20020032238A1 (en) 2000-07-08 2002-03-14 Henning Priepke Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
DE10033337A1 (de) 2000-07-08 2002-01-17 Boehringer Ingelheim Pharma Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2816940A1 (fr) 2000-11-23 2002-05-24 Lipha Derives de 4-(biphenylcarbonylamino)-piperidine, compositions les contenant et leur utilisation
GB0109287D0 (en) 2001-04-12 2001-05-30 Glaxo Group Ltd Therapeutic benzamide derivatives
TNSN03146A1 (fr) * 2001-06-28 2005-12-23 Pfizer Prod Inc Indoles, benzofurannes et benzothiophenes a substituant triamide, utiles comme inhibiteurs de secretion de la proteine de transfert des triglycerides microsomaux et/ou de l'apolipo-proteine b (apo b).
CN1630629B (zh) 2002-02-28 2010-05-05 日本烟草产业株式会社 酯化合物及其医药用途

Also Published As

Publication number Publication date
HUP0400348A3 (en) 2011-07-28
RS50712B (sr) 2010-06-30
DK1404653T3 (da) 2008-10-06
JP2004537541A (ja) 2004-12-16
HK1064369A1 (en) 2005-01-28
ES2307799T3 (es) 2008-12-01
KR100575944B1 (ko) 2006-05-02
CR7151A (es) 2004-02-23
US20050288335A1 (en) 2005-12-29
PA8549301A1 (es) 2003-02-14
AP2002002567A0 (en) 2002-06-30
DE60228447D1 (de) 2008-10-02
HRP20031051A2 (en) 2005-08-31
ZA200307818B (en) 2004-10-07
GT200200136A (es) 2003-05-15
WO2003002533A1 (en) 2003-01-09
HRP20031051B1 (en) 2012-01-31
MA27045A1 (fr) 2004-12-20
BG108487A (bg) 2005-04-30
TWI313264B (en) 2009-08-11
US7482368B2 (en) 2009-01-27
PL367680A1 (en) 2005-03-07
IL158516A0 (en) 2004-05-12
EE200400040A (et) 2004-06-15
GEP20063720B (en) 2006-01-10
AP1649A (en) 2006-08-07
CN1880304A (zh) 2006-12-20
KR100575919B1 (ko) 2006-05-02
NO20035607D0 (no) 2003-12-16
EP1404653B1 (en) 2008-08-20
CN1880304B (zh) 2010-11-24
ECSP034925A (es) 2004-02-26
CZ20033558A3 (cs) 2004-04-14
HU229551B1 (hu) 2014-01-28
CY1108407T1 (el) 2014-02-12
US6949572B2 (en) 2005-09-27
PT1404653E (pt) 2008-09-23
HK1096665A1 (en) 2007-06-08
MXPA03011707A (es) 2004-03-19
ATE405548T1 (de) 2008-09-15
GEP20053720B (en) 2006-01-10
KR20040013006A (ko) 2004-02-11
US6979692B2 (en) 2005-12-27
EA007008B1 (ru) 2006-06-30
JP4139325B2 (ja) 2008-08-27
CA2451474A1 (en) 2003-01-09
TNSN03146A1 (fr) 2005-12-23
PE20030135A1 (es) 2003-03-03
UY27360A1 (es) 2003-01-31
MY129328A (en) 2007-03-30
US20060194772A1 (en) 2006-08-31
EA200301310A1 (ru) 2004-06-24
BR0210616A (pt) 2004-09-28
US7348355B2 (en) 2008-03-25
EP1404653A1 (en) 2004-04-07
CN1522246B (zh) 2010-04-21
SK16102003A3 (sk) 2004-08-03
US20030187053A1 (en) 2003-10-02
HUP0400348A2 (hu) 2004-12-28
UA75660C2 (en) 2006-05-15
AU2002307839B2 (en) 2006-03-16
SI1404653T1 (sl) 2008-12-31
SK287806B6 (sk) 2011-10-04
US20040087625A1 (en) 2004-05-06
KR20060006107A (ko) 2006-01-18
CN1522246A (zh) 2004-08-18
OA12626A (en) 2006-06-13
US6720351B2 (en) 2004-04-13
TW200628447A (en) 2006-08-16
IS6988A (is) 2003-10-09
RS100403A (en) 2007-02-05
AR036158A1 (es) 2004-08-18
US20050080108A1 (en) 2005-04-14
IS2603B (is) 2010-04-15
NO326700B1 (no) 2009-02-02
NZ528752A (en) 2006-06-30
CA2451474C (en) 2009-06-16

Similar Documents

Publication Publication Date Title
EE05452B1 (et) Triamiidasendatud indoolid, bensofuraanid ja bensotiofeenid kui mikrosomaalse trigltseriidide transportvalgu (MTP) ja/v?i apolipoproteiin B (apoB) sekretsiooni inhibiitorid
NO20014823D0 (no) Heterocyklus-holdige bifenyl-aP2-inhibitorer og metode
LTPA2014028I1 (lt) Pakeistieji 3-cianochinolinai kaip proteintirozinkinazės inhibitoriai
CY2013005I2 (el) Κυκλικοι αναστολεις κινασης τυροσινης πρωτεϊνων
DE60221886D1 (de) 3-cyanochinoline als inhibitoren von egf-r- und her2-kinasen
ATE299881T1 (de) 4-substituierte 7-aza-indolin-2-one und ihre anwendung als protein kinase inhibitoren
NO20031161D0 (no) Chemokin-reseptorbindende heterocykliske forbindelser
DE60211601D1 (de) Bereitstellung von positionsabhängigen Inhalten
DE60210864D1 (de) Modifiziertes fluoreszentes Protein
ATE293477T1 (de) Neue verwendung von lipase-inhibitoren
DE60234956D1 (de) System zum transport von unbestrahlten kernbrennstabbündeln
EE200300266A (et) Asendatud 8-arüülkinoliinid kui fosfodiesteraas-4inhibiitorid
NO20042012L (no) Sammensetning og fremgangsmate for behandling av diabetes
DK1441761T3 (da) Fremgangsmåder til forebyggelse og behandling af flavivirus-infektion hos dyr
NO20014222D0 (no) Fremgangsmåte for behandling av COPD
DE60127648D1 (de) Methode und Einrichtung zur Beeinflussung von Lagerbelastungen
DE60025069D1 (de) Methode zur Verbesserung der Stabilität von aromatischen Polycarbodiimiden
NO20015791D0 (no) Arrangement og fremgangsmåte for definering og kontroll av meldingsdistribusjon
FI20010611A0 (fi) Menetelmä puutavaran kuivaamiseksi
FI20012399A (fi) Menetelmä ja järjestelmä sisällön aktivoimiseksi
NO20015203D0 (no) Isolerbar duk og fremgangsmåte for isolering av duk
FI20010384A0 (fi) Menetelmä massan valkaisussa ja massan valkaisulaitteisto
FIU20010446U0 (fi) Liimapuulevy
FI20010357A0 (fi) Menetelmä puutavaran kuivaamiseksi
SE0103177D0 (sv) Förfarande för höjning av säkerhet och effektivitet hos färdmedel

Legal Events

Date Code Title Description
HC1A Change of owner name
GB1A Change in the ownership or in the address of the owner
HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20150524